A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin's Regulation of Mitogenic Signaling and Tumor Suppressive Functions  by Yi, Chunling et al.
Cancer Cell
ArticleA Tight Junction-Associated Merlin-Angiomotin
Complex Mediates Merlin’s Regulation of Mitogenic
Signaling and Tumor Suppressive Functions
Chunling Yi,1 Scott Troutman,1 Daniela Fera,2,3 Anat Stemmer-Rachamimov,4 Jacqueline L. Avila,1 Neepa Christian,1
Nathalie Luna Persson,5 Akihiko Shimono,6 David W. Speicher,1 Ronen Marmorstein,2,3 Lars Holmgren,5
and Joseph L. Kissil1,*
1Molecular and Cellular Oncogenesis Program
2Gene Expression and Regulation Program
The Wistar Institute, Philadelphia, PA 19104, USA
3Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA
4Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
5Department of Oncology-Pathology, Cancer Center Karolinska Institutet, SE-17176 Stockholm, Sweden
6Cancer Science Institute of Singapore, National University of Singapore, Singapore 117456
*Correspondence: jkissil@wistar.org
DOI 10.1016/j.ccr.2011.02.017SUMMARYThe Merlin/NF2 tumor suppressor restrains cell growth and tumorigenesis by controlling contact-dependent
inhibition of proliferation. We have identified a tight-junction-associated protein complex comprising Merlin,
Angiomotin, Patj, and Pals1. We demonstrate that Angiomotin functions downstream of Merlin and upstream
of Rich1, a small GTPase Activating Protein, as a positive regulator of Rac1. Merlin, through competitive
binding to Angiomotin, releases Rich1 from the Angiomotin-inhibitory complex, allowing Rich1 to inactivate
Rac1, ultimately leading to attenuation of Rac1 and Ras-MAPK pathways. Patient-derived Merlin mutants
show diminished binding capacities to Angiomotin and are unable to dissociate Rich1 from Angiomotin or
inhibit MAPK signaling. Depletion of Angiomotin inNf2/ Schwann cells attenuates the Ras-MAPK signaling
pathway, impedes cellular proliferation in vitro and tumorigenesis in vivo.INTRODUCTION
Neurofibromatosis Type 2 (NF2), an autosomal dominant
disorder characterized by development of bilateral vestibular
schwannomas, is caused by mutations and loss of heterozy-
gosity (LOH) of the NF2 tumor suppressor gene (Hanemann,
2008). Biallelic NF2 inactivation also underlies various sporadic
tumors of the nervous system, including almost all schwanno-
mas, 50%–60% of meningiomas, and 29%–38% of ependymo-
mas (Hanemann, 2008). In corroboration of NF2’s inactivation as
an initiating factor for these tumors, mouse models specifically
deleting Nf2 in either Schwann or arachnoidal cellsSignificance
Inactivation of NF2/Merlin causes Neurofibromatosis Type 2 an
Merlin suppresses Ras-MAPK signaling by inhibiting Rac1 an
Merlin regulates Rac1 activity has remained elusive. We hav
complex, which mediates Merlin’s regulation of Rac1 activity
interacting with Angiomotin, Merlin prevents Angiomotin fro
Rac1-GTP to Rac1-GDP, thus delineating a signaling route co
Angiomotin plays a critical role in mediating tumorigenesis cau
as a therapeutic target in NF2/Merlin-related cancers.develop human-like schwannomas or meningiomas, respec-
tively (Giovannini et al., 2000; Kalamarides et al., 2002). Homozy-
gous somatic mutations of the NF2 gene have also been de-
tected in malignant mesothelioma (50%), thyroid (17%),
bladder (11%), skin (5%), stomach (5%), bone (3%), kidney
(2%), breast (2%), and intestine (2%) cancers (http://www.
sanger.ac.uk/perl/genetics/CGP/cosmic?
action=gene&ln=NF2).
TheNF2 gene encodes a 69 kDa protein calledMerlin (Moesin,
ezrin, and radixin like protein) that contains an N-terminal FERM
domain, followed by an a-helical domain and a charged
C-terminal tail. Under growth-permissive (sparse) conditions,d other sporadic cancers. Previous studies established that
d downstream effectors. However, the mechanism of how
e identified a tight-junction associated Merlin-Angiomotin
and downstream MAPK signaling. We demonstrate that by
m inhibiting Rich1, which inactivates Rac1 by converting
nnecting Merlin to Rac1. Importantly, our data indicate that
sed byNF2 inactivation, which could potentially be exploited
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Merlin/Angiomotin Regulation of Mitogenic SignalingMerlin is phosphorylated by p21-activated kinase 1 (Pak1) or
cAMP-dependent kinase A (PKA) on serine 518 within its
C-terminal tail (Alfthan et al., 2004; Kissil et al., 2002; Rong
et al., 2004; Xiao et al., 2002), which presumably prevents
binding of the FERM domain to the C-terminal tail, leaving Merlin
in an ‘‘open’’ and inactive conformation. Upon increased conflu-
ency and the formation of cell:cell contacts, Merlin is dephos-
phorylated by myosin phosphatase MYPT1-PP1d (Jin et al.,
2006), which is thought to convertMerlin to a ‘‘closed’’ and active
state. However, several recent studies have raised questions on
whether Merlin is indeed regulated by such conformational
changes (Hennigan et al., 2010; Lallemand et al., 2009; Schulz
et al., 2010).
As cells reach confluency, Merlin is recruited to cell junctions,
where it coordinates the establishment of intercellular contacts
with the concomitant inhibition of cell proliferation. The recruit-
ment ofMerlin to cell junctions is crucial for its tumor suppressive
function, as patient-derived mutations that impair Merlin junc-
tional localization render the protein inactive (Deguen et al.,
1998; Lallemand et al., 2003; Stokowski and Cox, 2000).
Although the exact mechanisms by which Merlin confers
contact-dependent inhibition of cell growth remain unclear, it
appears to involve regulation of receptor tyrosine kinases
(RTKs) and downstream mitogen-activated protein kinase
(MAPK) pathways. Several recent studies have illustrated that
loss of Merlin leads to accumulation of RTKs at the cell surface,
possibly due to defects in receptor trafficking (Ammoun et al.,
2008; Lallemand et al., 2009; Maitra et al., 2006). Alternatively,
Merlin has been suggested to inhibit RTKs by sequestering
them to microdomains of the plasma membrane (Curto et al.,
2007).
Downstream of RTKs, Merlin has been shown to inhibit Ras-
mediated activation of ERK/MAPK signaling (Ammoun et al.,
2008; Morrison et al., 2007). The full activation of ERK requires
the phosphorylation of c-Raf (serine 338) and MEK1 (serine
298) by the p21-activated kinases (Paks), the immediate down-
stream effectors of Rac1 (Beeser et al., 2005). Previous work by
our lab and others has shown that Merlin functions to inhibit
Rac1-mediated activation of Paks (Kissil et al., 2003; Xiao et al.,
2005). In addition to abnormal Pak1 activation, Merlin
deficiency in NF2 patients is associated with elevated levels of
Rac1-GTP, suggesting that Merlin has additional functions
upstreamof the Rac1-Pak axis (Kaempchen et al., 2003). Indeed,
expression of dominant-active Rac1 as well as dominant-active
Pak prevents Merlin from inhibiting Ras-induced activation of
MAPK signaling (Morrison et al., 2007). Another study has shown
thatMerlin inhibits contact-dependent recruitment of activeRac1
to the plasmamembrane in endothelial cells (Okada et al., 2005).
Thus, how Merlin coordinately regulates Rac1 and Ras signaling
from regions of cell:cell contact remains to be defined.
RESULTS
Merlin Associates with the Angiomotin/Patj/Pals1
Complex
To identify proteins that form stable complexes with Merlin, we
generated human embryonic kidney (HEK293) cell lines stably
expressing Flag-tagged Merlin. Affinity purification using Flag
antibody-coupled beads yielded a number of protein bands528 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.that specifically copurifiedwith Flag-Merlin (see Figure S1A avail-
able online). LC-MS/MS analysis identified these proteins as
Angiomotin (both p80 and p130 isoforms), Angiomotin-like 1,
Patj, and Pals1 (Figures S1B and S1C). Angiomotin (Amot),
Angiomotin-like 1 (Amotl1, also known as JEAP), and Angiomo-
tin-like 2 (Amotl2) form the Motin family. Interestingly, all
members of the Motin family have been shown to associate
with tight junctions (TJs) through binding to Patj and Pals1
(Ernkvist et al., 2009; Sugihara-Mizuno et al., 2007; Wells et al.,
2006). We focused on the characterization of Merlin-Angiomotin
interactions as the twoAngiomotin isoformsexhibited the highest
peptide match numbers in our purified Merlin-containing
complexes (Figure S1C).
Merlin Interacts Directly with Angiomotin through
Their Mutual Coiled-Coil Domains
HEK293 cells endogenously express Amot-p80 and Amot-p130.
We first verified that Merlin interacts with both isoforms of
Angiomotin by immunoprecipitation (IP) with Flag antibodies
from HEK293 cells transfected with expression vectors for
Flag-Angiomotin (either Amot-p80 or Amot-p130) (Figure 1A).
Tomap theMerlin-interacting domainwithin Angiomotin, we em-
ployed Amot-p80, which corresponds to the C-terminal half
(amino acids 410–1084) of Amot-p130 (Figure S1B). As shown
in Figure 1A and Figures S1B and S1D, whereas truncation
mutant of Angiomotin containing the coiled-coil (CC) domain
(p80CC) strongly interacts withMerlin, deletion of the CC domain
of Amot-p80 (p80DCC) abolishes its association with Merlin but
not with Patj. In contrast, the Amot-p80 (p80DC5) mutant lacking
the C-terminal PDZ binding motif (EYLI), which has previously
been shown to mediate its binding to Patj (Wells et al., 2006), still
interacts with Merlin while failing to bind to Patj (Figure 1A;
Figures S1B and S1D). To test whether by interacting with Merlin
and Patj through two distinct domains, Angiomotin serves as
a scaffold that recruits Merlin and Patj into the same complex,
we coexpressed Flag-Merlin and Patj-Myc in HEK293 cells
carrying control (–) or Amot shRNAs (+). As shown in Figure S1E,
IP of Patj-Myc fails to pull down Flag-Merlin when Angiomotin is
knocked down, suggesting that Merlin-Patj association is medi-
ated by Angiomotin. A previous study has shown that Angiomo-
tin complexes with Pals1 via Patj (Wells et al., 2006). Consistent
with this finding, we found that Merlin requires the coexpression
of both Angiomotin and Patj to coprecipitate with Pals1
(Figure S1F).
Merlin exists as two major isoforms in the cell, reported to
display differential interactions with some binding partners (Ra-
mesh, 2004). Compared with isoform 1, which was used in our
purification, Merlin isoform 2 has an altered C terminus due to
alternative splicing (Ramesh, 2004). Flag-IP from HEK293 cells
coexpressing Flag-Amot-p80 with HA-tagged Merlin indicated
that both isoforms of Merlin interact equally well with
Angiomotin (Figure 1B). Phosphorylation of Merlin at serine 518
has been linked to its growth suppressive activity (Okada et al.,
2005; Schulz et al., 2010; Shaw et al., 2001). Nonetheless, we
found that both S518A (unphosphorylated) and S518D (phos-
phomimicking) mutants of Merlin retain the ability to interact
with Angiomotin (Figure 1B).
To map the Angiomotin-binding domain within Merlin, we ex-
pressedvariousHA-taggedMerlin truncationmutants (Figure 1C)
Figure 1. Merlin Interacts with Angiomotin
through Their Mutual CC Domains
(A) Immunoblot (IB) analysis with Flag and Merlin
antibodies of Flag Immunoprecipitates (IP) and
total cell lysate fromHEK293 cells transfected with
various Flag-tagged Amot constructs as indi-
cated.
(B) IB analysis with Flag and HA antibodies of
Flag-IP and total cell lysate from HEK293 cells
cotransfected with Flag-Amot-p80 and HA-tag-
ged Merlin of either isoform (Iso1 or Iso2), or
S518A (S > A) and S518D (S > D) mutants as
indicated.
(C) Diagram of HA-tagged (represented by red
bars) full-length Merlin and deletion constructs
used in (D) below. S518 phosphorylation site is
marked by a purple line. The N-terminal FERM
domain is represented in yellow, the a-helical
region in green, and the C-terminal domain
(C-term) in blue. The Amot-binding status of each
construct is indicated by ‘‘+’’ (binding) or ‘‘–’’ (no
binding).
(D) IB analysis with HA and Flag antibodies of
HA-IP and total cell lysate of HEK293 cells co-
tranfected with Flag-Amot-p80 and various HA-
tagged Merlin constructs as indicated. Hatched
line indicates the merge of lanes from the same
images of the same experiment/blot with an irrel-
evant intervening lane deleted.
(E) IB analysis with Merlin and Amot antibodies of
Flag-IP and total cell lysate from HEK293 cells
transfected with Flag-tagged wild-type (WT) or
patient-derived mutant Merlin alleles as indicated.
(F) IB analysis with Amot, Merlin and Ezrin anti-
bodies of total cell lysate or IP with Amot antibody
or control IgG from HEK293 cells expressing
control (–) or sh-Amot (+).
(G) IB analysis with Merlin and GST antibodies
of GST pull-down of recombinant GST or GST-
Amot-p80 proteins incubated with recombinant
His-Merlin.
See also Figure S1.
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Merlin/Angiomotin Regulation of Mitogenic Signalingalongwith Flag-Amot-p80 in HEK293 cells. IP with HA antibodies
demonstrated that Merlin deletion mutants containing the pre-
dicted CC domains from either the a-helical region or the
C-terminal domain are able to bind to Angiomotin (Figures 1C
and 1D; Figure S1G). Furthermore, several alleles of Merlin
carrying patient-derived deletion or point mutations within the
a-helical region exhibited diminished affinity for Angiomotin (Fig-
ure 1E). These mutations do not affect Merlin’s interaction with
Pak1 (Figure S1H), which we have previously shown to be medi-
ated by the N-terminal FERM domain of Merlin (Kissil et al.,
2003). Taken together, these data suggest thatMerlin and Angio-
motin associate through their mutual CC domains.
We next confirmed that Angiomotin specifically interacts with
physiological levels of Merlin. IP with an Angiomotin antibody,
but not control IgG, pulled down endogenous Merlin along with
endogenous Angiomotin from wild-type HEK293 cells, while
only residual amounts of Merlin and Angiomotin were precipi-tated in HEK293 cells expressing Angiomotin shRNAs (Figure 1F;
Figure S1I). Ezrin, another CC-domain containing ERM protein,
did not coprecipitate with Angiomotin (Figure 1F), suggesting
that Angiomotin selectively interacts with Merlin.
To assess the extent of Merlin-Angiomotin interaction in cells,
we coexpressed Flag-Amot-p80 and Merlin tagged with both
Flag and HA in HEK293 cells. Immunoblotting (IB) analysis with
Flag antibody, which detects both exogenous Merlin and
Amot-p80, indicated similar levels of expression for both
proteins (Figure S1J, lower panel). By performing IP with HA anti-
body followed by IB with Flag antibody, we estimate that about
10%–20% of the total Angiomotin associates with Merlin in
HEK293 cells under these experimental conditions (Figure S1J,
upper panel).
Finally, through in vitro binding assays using purified recombi-
nant proteins, we demonstrated direct binding between Merlin
and Angiomotin (Figure 1G; Figure S4C). In attempts to estimateCancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc. 529
Figure 2. Merlin Colocalizes with Angiomotin to AJs and TJs in Epithelial Cells
(A) Immunofluorescence (IF) analysis of endogenous Merlin and ZO1 (upper panel), Amot and ZO1 (middle panel), or Merlin and Amot (lower panel) in HEK293
cells. Images were taken at 403 magnification.
(B and C) IF analysis of the endogenous localization of (B) Merlin (red) and ZO1 (green) or (C) Merlin (red) and E-Cad (green) in confluent MDCK cells. Confocal
images (upper panels) were taken at 1003 magnification. Deconvoluted Z-stacking images shown in lower panels.
(D) IF analysis of MDCK cells transfected with Flag-p80, Flag-p80DC5, or Flag-p130 with Flag and Merlin antibodies. Confocal images were taken at 1003
magnification.
Scale bars = 50 mm.
See also Figure S2.
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Merlin/Angiomotin Regulation of Mitogenic Signalingthe in vitro stoichiometry of the Merlin/Angiomotin complex by
gel filtration analysis, we found that free Angiomotin oligomerizes
into an apparent hexamer or higher-order species, whereas
Merlin exists primarily as a monomer, consistent with a recent
report (Hennigan et al., 2010; Figure S1K and data not shown).
The peak of the Merlin/Angiomotin complex runs too close to
the void volume to allow estimation of its molecular weight
(Figure S1K).
Angiomotin Retains Merlin at Mature TJs
in Epithelial Cells
Given the interaction between Merlin and Angiomotin in HEK293
cells, we examined the subcellular localization of endogenous
Merlin and Angiomotin in these cells by immunofluorescence
(IF). We first validated the specificity of Merlin and Angiomotin
antibodies using Merlin or Angiomotin knockdown (KD) or
knockout (KO) cells. As shown in Figures S2A–S2C, both anti-
bodies stained along cell boundaries in wild-type HEK293 or
primary mouse kidney (BMK) cells, and the respective signals530 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.were dramatically reduced or completely eliminated in Merlin
or Angiomotin KD/KO cells. Furthermore, endogenous Merlin
and Angiomotin colocalize with the TJ marker ZO1 and with
each other in HEK293 cells (Figure 2A), consistent with the two
proteins forming a complex at the TJs.
Merlin has been previously shown to localize to AJs in mouse
embryonic fibroblasts and keratinocytes (Lallemand et al.,
2003). The colocalization of Merlin with Angiomotin and ZO1
in HEK293 cells suggests that Merlin also localizes to TJs.
Since HEK293 cells do not form mature belt-like junctional
structures, we switched to MDCK cells to further characterize
Merlin and Angiomotin localization. Costaining of endogenous
Merlin with either E-Cadherin (an AJ marker) or ZO1 (a TJ
marker) and subsequent confocal Z-stack analysis along the
apical-basolateral axis revealed that Merlin partially colocalized
with both AJ and TJ markers in MDCK cells (Figures 2B and
2C). Similarly, Angiomotin localization has been shown to over-
lap with both AJ and TJ markers in MDCK cells (Wells et al.,
2006).
Figure 3. Merlin Functions through Angiomotin and Rich1 to Inhibit
Rac1 and Ras-MAPK Signaling
(A) IB analysis of cell lysates from HEK293 cells stably expressing vector
control (Ctrl) or two independent Angiomotin shRNAs (Amot-KD) with different
antibodies as indicated. Tubulin used as internal loading control.
(B) IB analysis of cell lysate fromHEK293 cells stably expressing vector control
(Ctrl) or Angiomotin shRNAs (Amot-KD, clone #8) that were transfected with
nonsilencing control siRNAs (–) or siRNAs targeting Merlin or Rich1 (+). Total
MEK protein used as internal loading control.
(C) IB analysis of cell lysate from HEK293 cells transiently transfected with
Flag-Merlin with (+) or without (–) siRNAs targeting Rich1. Tubulin used as
internal loading control.
(D) IB analysis of cell lysate fromHEK293 cells transiently transfectedwith non-
silencing control siRNAs (–) or siRNAs targeting Rich1 or Pak (+). Total MEK
used as internal loading control.
(E) IB analysis of cell lysate from HEK293 cells stably expressing vector control
(Ctrl) or Angiomotin shRNAs (Amot-KD, clone #8) that were transfected with
empty vector (–) or constitutive-active form of Pak3 (+). Total MEK used as
internal loading control.
Cells were serum starved overnight and stimulated with 10 ng/ml EGF for 50 in
(A)–(E). Data shown are representative of three independent experiments.
(F) Schematic representation of the Merlin-Angiomotin-Rich1-Rac1-Pak
signaling cascade in relation to the Ras-ERK pathway. The dotted curved line
reflectspreviousfindingsshowing thatMerlincanalsodirectly inhibitPakactivity
and, in a negative feedback loop, Pak phosphorylates and inactivates Merlin.
See also Figure S3.
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Merlin/Angiomotin Regulation of Mitogenic SignalingTo study its recruitment kinetics to cell junctions, the localiza-
tion of Merlin was examined following a calcium switch. In brief,
after overnight incubation in Low Calcium Medium (LCM),cells were switched back to High Calcium Medium (HCM) and
fixed at different time points. We have previously shown that
both Angiomotin isoforms were recruited to the junctions several
hours after switching to HCM in MDCK cells (Ernkvist et al.,
2008). In contrast, Merlin regained junctional localization as early
as 15 min after the switch, similar to ZO1 (Figure S2D). At this
point in time, only primordial junctional structures would have
been formed (Miyoshi and Takai, 2005). This early recruitment
of Merlin to the primordial junctions is likely mediated
by E-cadherin or b-catenin, proteins that have been shown to
interact with Merlin (Curto et al., 2007; Lallemand et al., 2003).
Although Angiomotin does not appear to participate in the
initial recruitment of Merlin to primordial junctions, it may control
the subsequent redistribution of a portion of Merlin to mature
TJs. To address this possibility, we transfected MDCK cells
with Flag-tagged Angiomotin p80, p130, or p80DC5. As shown
in Figure 2D, cells overexpressing Angiomotin p80 or p130
exhibited increased localization of endogenous Merlin to TJs,
compared to neighboring untransfected cells. In contrast,
overexpression of p80DC5 without the TJ-tethering domain
resulted in a significant shift of Merlin from cell junctions to peri-
junctional regions in the cytoplasm (Figure 2D). As a control, we
transfected MDCK cells with Flag-p80DCC, which is localized
throughout the cytoplasm, but not to the cell junctions (Fig-
ure S2E). Consistent with our finding that p80DCC does not
interact with Merlin (Figure 1A; Figure S1D), the distribution of
Merlin in p80DCC-transfected cells was essentially indistin-
guishable from surrounding untransfected cells (Figure S2E).
Taken together, these data suggest that, while the recruitment
of Merlin to early junctional structures likely does not involve
Angiomotin, the retention of Merlin at mature TJs is mediated
by Angiomotin.Angiomotin Functions Downstream of Merlin
and Upstream of Rich1 as a Positive Regulator
of Rac1 and MAPK Signaling
A similar TJ-associated protein complex containing Angiomotin,
Patj, and Pals1 has previously been purified from HEK293 cells
using a RhoGAP domain containing protein, Rich1 (also known
as ARHGAP17 or Nadrin), as bait (Wells et al., 2006). In this
report, the authors showed that Rich1 functions as a Cdc42
GAP and that Angiomotin, through direct interaction with
Rich1, negatively regulates the GAP activity of Rich1. Two other
studies reported that Rich1 is also active toward Rac1 (Harada
et al., 2000; Richnau and Aspenstrom, 2001). To determine the
activity of Rich1 in HEK293 cells, we used siRNAs to knockdown
endogenous Rich1 expression and examined endogenous
Rac1-GTP and Cdc42-GTP levels. As shown in Figure S3A,
depletion of Rich1 in HEK293 cells increased the endogenous
levels of active Rac1 without affecting Cdc42 activity. In
contrast, Angiomotin knockdown (Amot-KD) HEK293 cells ex-
hibited a decrease in endogenous Rac1-GTP, while levels of
active Cdc42 remained unchanged (Figure 3A; Figure S3B).
These results suggest that Rich1 and Angiomotin regulate
Rac1-GTP levels in HEK293 cells, but do not exclude the possi-
bility that they may also modulate Cdc42-GTP levels in other cell
types, as shown by other studies (Harada et al., 2000; Wells
et al., 2006).Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc. 531
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Merlin/Angiomotin Regulation of Mitogenic SignalingMerlin has been previously shown to function as a negative
regulator of Rac1, through which it inhibits the phosphoryla-
tion/activation of Ras-MAPK signaling effectors such as c-Raf,
MEK1/2 and ERK (Ammoun et al., 2008; Morrison et al., 2007).
Based on our finding that Angiomotin and Rich1 also modulate
Rac1 activity (Figure 3A; Figures S3A, and S3B), we focused
on how Merlin, Angiomotin, and Rich1 may function together
to regulate Rac1 and Ras-MAPK signaling.
To determine whether Angiomotin indeed plays a role in
regulating MAPK signaling, we introduced two independent
shRNAs targeting both isoforms of Angiomotin either sepa-
rately or in combination (Amotsh #1, #2, or #1 + #2) into
HEK293 cells and found that both shRNAs reduced the levels
of endogenous Angiomotin and led to a decrease in pERK
(T202/204) levels, which was rescued by the reintroduction of
either Angiomotin isoform (Figures S3C and S3D). As combina-
tion of the two shRNAs resulted in an almost complete deple-
tion of endogenous Angiomotin, we established two indepen-
dent HEK293 lines (Amot-KD #2 and #8) stably expressing
both Amot shRNAs and carried out subsequent studies with
these two clones. In addition to lowering the levels of Rac1-
GTP, silencing of Angiomotin led to decreased phosphorylation
of c-Raf (S338), MEK (S298), ERK (T202/204), p95RSK (S380),
and BAD (S112), all of which are phosphorylation sites associ-
ated with an activated state of the MAPK pathway (Figures 3A
and 3F; Figure S3E). In contrast, the phosphorylation of BAD
(S136), a phosphorylation event downstream of PI3K-AKT
signaling, was unaffected by Angiomotin diminution (Fig-
ure S3E). These data indicate that Angiomotin regulates the
Rac1-Pak axis and downstream MAPK signaling in an opposite
manner from Merlin and Rich1.
To establish the hierarchy of Merlin, Angiomotin, and
Rich1 in controlling Rac1 and MAPK signaling, we introduced
a ‘‘smartpool’’ or deconvoluted siRNAs targeting Merlin and/or
Rich1 into control or Amot-KD HEK293 cells and assessed
Rac1 activity and MAPK signaling in these cells. Consistent
with Merlin and Rich1 acting as negative regulators, knockdown
of either endogenous Merlin or endogenous Rich1 in wild-type
HEK293 cells elevated the levels of active Rac1, phospho-
MEK and phospho-ERK (Figure 3B; Figures S3F and S3G).
Notably, simultaneous depletion of Merlin and Rich1 did not
further enhance Rac1 activity and downstream MAPK signaling
(Figure 3B), suggesting that the two proteins function within
a linear pathway. In Amot-KD HEK293 cells, while silencing of
Merlin failed to reverse the downregulation of Rac1-GTP levels
and MAPK signaling caused by the loss of Angiomotin, elimina-
tion of Rich1 restored the levels of Rac1-GTP and MEK/ERK
phosphorylation to near those of control cells (Figure 3B), thus
placing Angiomotin downstream of Merlin and upstream of
Rich1 in modulating Rac1 activation and Ras-MAPK signaling
(Figure 3F).
To assess whether Rich1 indeed mediates Merlin’s regulation
of Rac1 and the MAPK pathway, we cotransfected Flag-Merlin
with either a nonsilencing control or Rich1 siRNAs into HEK293
cells. As shown in Figure 3C, overexpression of Flag-Merlin
reduced the levels of active Rac1 and phosphorylated c-Raf
and ERK in cells cotransfected with control siRNAs, but not in
cells coexpressing Rich1 siRNAs. Therefore, Merlin requires
Rich1 to inhibit Rac1 and MAPK signaling.532 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.Finally, we confirmed that Angiomotin and Rich1 function
through the Paks to regulate the MAPK pathway. As shown in
Figures 3D and 3E, expression of Pak-specific siRNAs or
a constitutive active form of Pak (CA-Pak3) eliminated the effects
of Rich1 or Amot knockdowns on MAPK signaling, respectively.
Merlin Negatively Regulates Rac1 Activity and MAPK
Signaling by Competing with Rich1 for Angiomotin
Binding
Our data so far have established a regulatory pathway
upstream of Rac1, in which Merlin, Angiomotin, and Rich1 func-
tion as upstream inhibitors of each other (Figure 3F). Consid-
ering that Angiomotin interacts with Merlin through its CC
domain (Figure 1A), which also mediates Angiomotin-Rich1
binding (Wells et al., 2006), we hypothesized that Merlin might
function as an activator of Rich1 by dissociating it from its inhib-
itor Angiomotin. To test this hypothesis, we transfected HEK293
cells with Myc-Rich1, HA-Merlin, and Flag-Amot-p80 and
carried out IP with either Myc, HA, or Flag antibodies. As shown
in Figure 4A, Flag-Amot-p80 coprecipitated with both HA-
Merlin and Myc-Rich1, thus corroborating that Angiomotin
interacts with both Merlin and Rich1. In contrast, HA-Merlin
and Myc-Rich1 did not coprecipitate, indicating that Merlin
and Rich1 form distinctive complexes with Angiomotin. Simi-
larly, in vitro binding assays employing purified recombinant
proteins showed that Merlin and Rich1, while not interacting
with each other, both directly bind to Angiomotin (Figure 1F;
Figures S4C and S4D).
To examine whether Merlin and Rich1 compete for interaction
with Angiomotin, HA-Merlin, and Myc-Rich1 expression vectors
were introduced into HEK293 cells either separately or together,
and endogenous Angiomotin was precipitated from these cells
and probed with Angiomotin, HA, and Myc antibodies. Whereas
a similar amount of HA-Merlin was present in Angiomotin precip-
itates from cells expressing HA-Merlin alone or in combination
with Myc-Rich1, the amount of Myc-Rich1 coprecipitated with
Angiomotin was drastically diminished when HA-Merlin was
coexpressed (Figure 4B), suggesting that Merlin competes with
Rich1 for binding to Angiomotin.
To further assess how Merlin competes with Rich1 for Angio-
motin binding, we expressed Merlin at increasing levels and
analyzed Rich1-Angiomotin interactions in HEK293 cells. We
found that Merlin reduces Rich1-Angiomotin association and
MAPK signaling in a dose-dependent manner (Figure 4C). Simi-
larly, addition of increasing amount of recombinant Merlin
protein gradually titrates Angiomotin off Rich1 in vitro (Fig-
ure S4D). Importantly, tumor-derived Merlin mutants that are
defective in Angiomotin binding fail to displace Rich1 from An-
giomotin (Figures 1E and 4D), suggesting that the interplay
between Merlin, Angiomotin, and Rich1 mediates, at least in
part, the tumor suppressive function of Merlin.
Based on the NCBI gene database, Rich1 is expressed as at
least five splice isoforms in mouse, whereas in human only two
Rich1 splice isoforms have been reported to date. In light of
a previous account suggesting that different Rich1 isoforms
may have distinct functions and tissue distributions (Furuta
et al., 2002), we evaluated whether Merlin and Angiomotin may
differentially regulate the two major isoforms of human Rich1.
As shown in Figure S4A, we found no significant distinction
Figure 4. Merlin Competes with Rich1 for Association with
Angiomotin
(A) IP and IB analysis of cell lysates from HEK293 cells cotransfected with HA-
Merlin, Flag-Amot-p80, and Myc-Rich1 with HA, Flag, or Myc antibodies as
indicated.
(B) IB analysis of endogenous Angiomotin IP from HEK293 cells expressing
equal amounts of HA-Merlin and Myc-Rich1 alone or in combination. Normal
rabbit IgG used as negative control.
(C) IB analysis of Myc-Rich1 and Flag-Merlin coprecipitated with endogenous
Angiomotin and of total cell lysates from HEK293 cells expressing fixed
amount of Myc-Rich1 (10mg) and incremental amount of Flag-Merlin (0, 1, 2.5,
5, and 10 mg from left to right) with antibodies as indicated.
(D) IB analysis of Myc-Rich1 and Flag-Merlin coprecipitated with endogenous
Angiomotin and total cell lysate from HEK293 cells expressing Myc-Rich1
alone or in combination with Flag-tagged wild-type or mutant Merlin alleles as
indicated. Normal rabbit IgG used as negative control.
(E) IB analysis with indicated antibodies of Angiomotin IP and total cell lysate
from HEK293 cells coexpressing Flag-Merlin and Myc-Rich1 under confluent
(C), sparse (Sp), serum-stimulated (St), or suspension (Su) conditions. Normal
rabbit IgG used as negative control. TotalMEKused as internal loading control.
See also Figure S4.
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affinities for Rich1. Likewise, both isoforms of Rich1 interact
similarly with endogenous Angiomotin (Figure S4B). Neverthe-less, coexpression of Merlin reduced the binding of Rich1
isoform 2 to Angiomotin to a larger extent than Rich1 isoform
1 (Figure S4B).
In search of physiological signals that might modulate the
interaction of Angiomotin with Merlin and/or Rich1, we trans-
fected HEK293 cells with Flag-Merlin and Myc-Rich1 and
compared the amount of Merlin and Rich1 coprecipitated
with endogenous Angiomotin under various growth conditions.
Since Angiomotin colocalizes with both Merlin and Rich1 at the
site of cell junctions (Figure 2A) (Wells et al., 2006), we as-
sessed whether cell-cell contacts are required for Angiomotin
to interact with either protein. Not surprisingly, in comparison
to confluent cultures (C), sparsely grown cells (Sp) or cells
grown in suspension (Su) show reduced interactions between
both Angiomotin-Merlin and Angiomotin-Rich1 (Figure 4E),
corroborating that establishment of cell junctions facilitates
the assembly of Angiomotin-Merlin and Angiomotin-Rich1
complexes. Under confluent conditions that allow the formation
of junctional structures, we found that serum starvation fol-
lowed by brief exposure to serum (St) dissociates Merlin from
Angiomotin, while increasing the amount of Angiomotin-bound
Rich1 and corresponding pMEK (S298) levels (Figure 4E).
These data indicate that Angiomotin interacts dynamically
with Merlin or Rich1 in response to cues from the extracellular
environment, although the molecular mechanisms underlying
these changes remain to be elucidated. Finally, the high level
of MAPK signaling under sparse conditions, which disrupt
Angiomotin-Merlin and Angiomotin-Rich1 complexes (Fig-
ure 4E), underscores the spatial and temporal constraints under
which the Merlin-Angiomotin-Rich1 signal cascade operates
and the existence of additional regulatory mechanisms on
Rac1 activity and MAPK signaling under certain physiological
conditions.
Angiomotin and Merlin Interact in Schwann Cells
and Colocalize to Paranodes and Schmidt-Lantermann
Incisures in the Myelinating Peripheral Nerve
Patients with mutations in the NF2 gene develop primarily
Schwann cell tumors of peripheral nerves. Thus, to ascertain
the potential relevance of the Merlin-Angiomotin interaction to
the tumor suppressive functions of Merlin, we first confirmed
that Angiomotin, similar to Merlin, is expressed in Schwann cells
(rat R3 Schwann cells, rat RT4 schwannoma cells and human
MPNST 90-8TL cells) and human peripheral nerve tissue (Figures
S4E and S4F).
To investigate whether Merlin and Angiomotin interact in
Schwann cells, we carried out IP using Merlin or Angiomotin
antibodies in RT4-67 schwannoma cells that carry a doxycy-
cline-inducible allele of Merlin. In the absence of doxycycline,
endogenous Merlin and Angiomotin readily coprecipitated with
one another (Figure 5A). Upon treatment with doxycycline,
increase in Merlin expression led to a corresponding increase
in the amount of Angiomotin or Merlin coprecipitated with one
another, but not with control IgGs (Figure 5A). Likewise, endo-
genous Merlin-Angiomotin interactions are also detectable in
rat R3 and human 90-8TL cells (Figure S4F).
To examine the distribution of Angiomotin andMerlin along the
highly polarized myelinating Schwann cells in vivo, we dissected
sciatic nerve fibers from wild-type mice and stained them withCancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc. 533
Figure 5. Merlin Interacts and Colocalizes with Angiomotin in Schwannoma Cells and Myelinating Peripheral Nerves
(A) IP and IB analysis with Amot or Merlin antibodies of cell lysates from untreated (–) or Doxycyline induced (+) RT4-67 cells as indicated.
(B) IF analysis of teased nerve fibers isolated frommouse sciatic nerves for Amot and E-cadherin (E-cad), or Merlin and E-cad as indicated. Arrowheads indicate
the Schmidt-Lantermann incisures and paranodes. Images were taken at 403 magnification. Scale bar = 50 mm.
(C) IB analysis of Raf and ERK activation in cell lysates from RT4 cells transfected with vector control or Flag-tagged wild-type or mutant Merlin as indicated.
(D) IB analysis of Myc-Rich1 and Merlin coprecipitated with endogenous Angiomotin and total cell lysates from RT4-67 cells expressing fixed amount of
Myc-Rich1 (10 mg) and treated with increasing dose of Doxycyline (0, 50, 100, 250, and 500 ng/ml from left to right) as indicated.
(E) IB analysis with indicated antibodies of Angiomotin IP or total cell lysate from untreated (–Dox) or Doxycyline induced (+Dox) RT4-67 transfected with
Myc-Rich1 and grown under confluent (C), sparse (Sp), or serum-stimulated (St) conditions.
See also Figure S4.
Cancer Cell
Merlin/Angiomotin Regulation of Mitogenic SignalingAngiomotin, Merlin, and E-cadherin antibodies. As shown in Fig-
ure 5B, both Angiomotin andMerlin colocalize with E-cadherin to
the paranodes and Schmidt-Lantermann incisures along the
sciatic nerves. Thus, Merlin and Angiomotin interact and coloc-
alize in myelinating Schwann cells, the cell type of origin for
NF2-associated schwannomas.
Consistent with the hypothesis that Merlin-Angiomotin
interaction is necessary for Merlin to suppress Ras-MAPK
signaling, we found that patient-derived Merlin mutants defec-
tive in Angiomotin-binding (Figure 1E) also lose the capacity to
inhibit c-Raf and ERK phosphorylation in RT4-67 cells (Fig-
ure 5C). As in HEK293 cells (Figure 4C), Doxycycline-induced
expression of Merlin in RT4-67 cells leads to a gradual decrease
in Angiomotin/Rich1 association (Figure 5D). Furthermore,534 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.formation of cell:cell contacts in RT4-67 cells are also required
for the assembly of the Angiomotin/Merlin complex, which is
disrupted upon serum stimulation (St), leading to an increase in
Angiomotin/Rich1 association (Figure 5E). These results indicate
that Merlin operates through Angiomotin and Rich1 to inhibit
MAPK signaling in Schwann cells.Depletion of Angiomotin Impedes the Proliferation and
Tumorigenic Capacity of Nf2-Deficient Schwann Cells
The findings that Merlin and Angiomotin interact and colocalize
in Schwann cells and that Merlin functions through Angiomotin
to regulate growth factor mediated signaling (Figure 5) strongly
suggest that deregulation of Angiomotin in NF2-deficient
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Merlin/Angiomotin Regulation of Mitogenic SignalingSchwann cells may contribute to tumor development caused by
the loss of NF2.
To investigate whether Angiomotin is required for tumor
development in vivo, we employed a mouse model of NF2 in
which conditional deletion of Nf2 in mouse Schwann cells
(P0-Cre:Nf2flox/flox) leads to schwannoma development, within
a lag time of several months (Giovannini et al., 2000). To assess
the requirement for Angiomotin in this model, we crossed
the P0-Cre and P0-Cre:Nf2flox/flox to Amotflox/flox mice. While
P0-Cre:Amotflox/flox mice are born at the expected Mendelian
ratios and develop normally, the P0-Cre:Nf2flox/flox :Amotflox/flox
mice die shortly after birth due to neurological defects (C.Y.
and J.L.K., unpublished data), precluding the use of this model.
We therefore employed instead an orthotopic mouse model in
which Schwann cells are injected intraneurally into the mouse
sciatic nerve (Wong et al., 2010). First, we introduced two inde-
pendent constructs expressing Angiomotin shRNAs into Nf2
null Schwann cells (SC4) that were derived from the sciatic
nerves of Nf2flox/flox mice and treated with Adeno-Cre in vitro to
delete the Nf2 gene (Lallemand et al., 2009). As shown in Fig-
ure S5A, a significant reduction in Angiomotin protein levels
was observed in cells expressing either of the two shRNAs (sh-
Amot #1 and #2). This was accompanied by a dramatic decrease
in levels of phospho-MEK and phospho-ERK and led to approx-
imately a 2-fold reduction in the growth rate of the Amot-KD SC4
cells (Figure S5B). This apparent decrease in growth rate is not
due to secondary effects caused by reduced attachment or
cell viability, as we observed no evidence of cell detachment
(data not shown) or apoptosis in Amot-KDSC4cells (Figure S5C).
Previous studies have shown that loss of Merlin increases cell
proliferation by promoting G1 to S phase progression (Okada
et al., 2005; Xiao et al., 2005). To examine whether Angiomotin
silencing slows the proliferation of SC4 cells by overriding the
effect of Nf2 deficiency on cell cycle progression, we carried
out a BrdU incorporation assay to compare the abilities of an
G0-synchronized control and Amot-KD SC4 cells to progress
through G1 phase and into S phase in response to mitogenic
cues. As shown in Figures 6A–6C, depleting Amot from Nf2
null SC4 cells, similar to Merlin reconstitution, resulted in
reduced BrdU incorporation rate and ERK phosphorylation,
comparing to control SC4 cells. Furthermore, ablation of Angio-
motin from SC4 cells with restored Merlin expression did not
further lower the BrdU incorporation rate (Figures 6A and 6B),
suggesting that inactivation of Angiomotin specifically inhibits
the proliferation of Nf2-deficient SC4 cells.
Next, to examine whether Angiomotin is required for tumor
development driven by Nf2 deficiency, control and Amot-KD
SC4 cells carrying a luciferase reporter allele were injected intra-
neurally into the sciatic nerve sheaths of NOD/SCID mice, and
tumor development was monitored through bioluminescence
imaging (BLI). As shown in Figures 6D and 6E, 1 week post
surgery, substantial tumor growth was detectable in mice trans-
planted with control SC4 cells. In comparison, at this time point,
tumor development was minimal for either of the Amot-KD lines.
We also carried out an extended time course study and found
that tumors from Amot-KD SC4 cells continued to grow at
a significantly slower rate than those from control SC4 cells up
to 3 weeks post surgery, at which timemice injected with control
SC4 cells had to be sacrificed (Figure S5D). We analyzed threetumors from each of the control and two Amot-KD groups by
western blot analysis and found that with the one exception,
the majority of Amot-KD tumors maintained low levels of Amot
and MAPK signaling, consistent with their slower growth rate
(Figure S5E). To characterize how the orthotopic tumors invade
normal sciatic nerves, we performed immunohistochemistry
(IHC) with neuronal marker Tuj-1 that stains only normal nerves,
and Schwann cell marker p75NTR, which marks both tumor and
host nerve tissues. As shown in Figure S5F, tumors derived from
control SC4 cells only contain remnants of nerve structures,
which are positive for p75NTR but negative for Tuj-1. In contrast,
a number of mostly intact nerve bundles positive for both
p75NTR and Tuj-1 were scattered across the Amot-KD tumors,
suggesting that Amot-KD results in a less aggressive tumor
phenotype. Similar effects of Amot-KD on tumor growth rates
were observed in a xenograft study in which control and Amot-
KD SC4 cells were subcutaneously injected side by side into
the flanks of NOD-SCID mice (Figures S5G and S5H).
Taken together, these data demonstrate that Angiomotin is
required for schwannoma development due to loss of Nf2 and
warrant further testing of Angiomotin as a potential therapeutic
target in NF2-driven schwannomas.DISCUSSION
The Antagonizing Angiomotin/Merlin and Angiomotin/
Rich1 Signaling Complexes Link TJs to Regulation
of Growth Factor Signaling
In addition to its well-characterized role as a permeability barrier,
the TJs, mostly through the so-called ‘‘TJ cytoplasmic plaque,’’
also serve as a platform that integrates multiple signal transduc-
tion pathways regulating cytoskeleton organization, cell polarity,
cell proliferation, and cell differentiation (Iden and Collard, 2008).
It is well established that the formation of junctional structures
upon cell:cell contacts is pivotal to the concomitant suppression
of mitogenic signaling. Disruption of TJs leads to uncontrolled
cell proliferation and represents an early and key aspect in
cancer metastasis, although the exact mechanisms are unclear
(Forster, 2008). In this study, we have identified a TJ-associated
signaling complex, in which Merlin is connected to the junctional
proteins Patj and Pals1 via Angiomotin (Figure S1). Intriguingly,
we find that this Merlin-containing junctional complex negatively
regulates another TJ-associated Rich1/Angiomotin/Patj/Pals1
complex in response to environmental signals (Figures 4 and
5). Taken together with our other finding that Merlin, Angiomotin
and Rich1 function to regulate Rac1 activity and MAPK signaling
in a hierarchical manner (Figure 3), we propose the following
working model: under growth suppressive conditions such as
the maturation of cell junctions, Merlin releases Rich1 from
Angiomotin, allowing Rich1 to inhibit Rac1 activity by converting
Rac1-GTP to Rac1-GDP (Figure 7, left panel). In response to
growth stimuli, Merlin becomes dissociated from Angiomotin
through a yet unidentified mechanism. Unoccupied Angiomotin
sequesters Rich1 at TJs, leading to an increase in Rac1 activity
(Figure 7, right panel). Our finding that by forming competitive
complexes with Angiomotin at the TJ cytoplasmic plaque, Merlin
and Rich1 inhibit Rac1 and the Ras-MAPK mitogenic pathways
provides initial clues as to how TJs might coordinately regulateCancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc. 535
Figure 6. Angiomotin Knockdown Inhibits the Proliferation and Tumorigenicity of Nf2–/– Schwann Cells
(A) Representative fields of BrdU (green) and DAPI (blue) double staining of Nf2/ SC4 cells or Merlin-reconstituted SC4 cells (Nf2/+retroNf2) infected with
control (Ctrl) or Angiomotin shRNAs (sh-Amot #1 or #2). Cells were serum starved for 24 hr followed by incubation with BrdU in the presence of serum for 18 hr.
Images were taken at 403 magnification. Scale bar = 50 mm.
(B) Quantitative analysis of the percentage of BrdU positive cells from (A). Each bar represents the average percentage of BrdU+ cells of 5 random fields from each
cell line. Error bars indicate standard deviation (SD). p value was calculated with two-tailed unpaired Student’s t test.
(C) IB analysis of ERK activation in Nf2/ SC4 cells or Merlin-reconstituted SC4 cells (Nf2/+retroNf2) infected with control (Ctrl) or Angiomotin shRNAs
(sh-Amot #1 or #2). Total ERK used as internal loading control.
(D) Representative images from bioluminescence imaging (BLI) of orthotopic tumors derived from control SC4/pLuc-mCherry cells (Ctrl) or Amot-KD SC4/pLuc-
mCherry (Amot-KD) cells injected into sciatic nerve sheaths of NOD/SCID mice.
(E) Quantitative analysis of the total flux of luciferase signal from areas of injection. The sciatic nerves of three groups (N = 5) of NOD/SCID mice were injected
intraneurally with 23 105 Ctrl SC4/pLuc-mCherry or Amot-KD SC4/pLuc-mCherry cells (line #1 or line #2). All mice were imaged by BLI 1 week after the surgery.
p value was calculated with two-tailed unpaired Student’s t test.
See also Figure S5.
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and suppression of cell proliferation.
The Multifaceted Merlin Signaling Network
Weand others have previously shown thatMerlin can inhibit Rac1
signalingby interferingwith theactivationof thePaksbyRac1 (Hir-
okawaetal., 2004;Kissil et al., 2003;Xiaoetal., 2005). Inanegative
feedback loop, the Paks in turn phosphorylates and inactivates
Merlin (Kissil et al., 2002; Xiao et al., 2002). Additionally, it has
been shown that Merlin mediates contact-dependent inhibition536 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.of cell proliferation by acting upstream of Rac1 and MAPK
signaling, although the exact mechanism of how Merlin controls
Rac1 activity was not defined (Morrison et al., 2007; Okada
et al., 2005). The TJ-associated Merlin-Angiomotin-Rich1-Rac1-
Pak signaling cascade delineated by our study provides amecha-
nism to explainMerlin’s regulation of Rac1 (Figure 7). Notably, our
current study yet again points toward the Rac1-Pak axis as a crit-
ical mediator of Merlin signaling and is consistent with our
previous work demonstrating that inhibition of Pak can counter
the tumorigenic effect of Merlin inactivation (Yi et al., 2008).
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Figure 7. Merlin Inhibits Rac1 Activity by Releasing Rich1 from Its TJ-Associated Inhibitor, Angiomotin
A model depicting the proposed mechanism of how the differential interactions between Merlin, Angiomotin and Rich1 modulate Rac1 activity. Under growth
suppressive conditions, Merlin binds to Angiomotin, releasing Rich1 to inactivate Rac1 by converting Rac1-GTP to Rac1-GDP. In response to growth stimuli,
Merlin dissociates from Angiomotin. Unoccupied Angiomotin binds to and blocks Rich1’s GAP activity, leading to increased levels of Rac1-GTP.
Cancer Cell
Merlin/Angiomotin Regulation of Mitogenic SignalingIn addition to inhibiting the Rac1-Pak axis, Merlin’s tumor
suppressive activity has been linked to growth factor receptor
signaling and the Hippo/Yap pathway (Benhamouche et al.,
2010; Yi and Kissil, 2010; Zhang et al., 2010). Furthermore,
a recent study has showed that Merlin has additional nuclear
function in inhibiting the CRL4DCAF1 E3 ubiquitin ligase, which
is also important for Merlin’s tumor suppressive activity
(Li et al., 2010). Therefore, the emerging picture of Merlin’s
tumor suppressive function is one of significant complexity.
Considering that Pak, EGFR, DCAF1, and now Angiomotin
have been all shown to be required for the tumor suppressivefunction of Merlin, it is likely that these seemingly parallel path-
ways are in fact interdependent of each other and further
efforts to elucidate the relationships between these pathways
will greatly facilitate the understanding of Merlin’s tumor
suppressive function.
We find that in contrast to Pak and DCAF1, which bind to the
N-terminal FERM domain of Merlin, Angiomotin interacts with
Merlin through its C-terminal CC domains (Figures 1C–1E).
Also unlike DCAF1, the Merlin-Angiomotin interaction does not
appear to be affected by S518 phosphorylation (Figure 1B).
Nonetheless, phosphorylation could still potentially play a roleCancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc. 537
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Merlin/Angiomotin Regulation of Mitogenic Signalingin modulatingMerlin-Angiomotin interaction, as additional Merlin
phosphorylation sites have been described previously (Kissil
et al., 2002; Shaw et al., 2001). Notably, we observed a slower
migrating (presumably hyperphosphorylated) form of the Merlin
S518D mutant that did not coprecipitate with Angiomotin
(Figure 1B). This is consistent with a scenario in which phosphor-
ylation at S518 primes Merlin for further posttranslational modi-
fication(s), which in turn block(s) Merlin’s binding to Angiomotin.
Clearly, further studies are necessary to investigate this and
other potential mechanism(s) that control(s) Merlin’s ability to
interact with Angiomotin.
Our findings that the CC domains of Merlin from both the
a-helical and C-terminal regions can mediate its binding to
Angiomotin (Figures 1C and 1D; Figure S1G) and that tumor-
derived mutations within the a-helical region abate Merlin-
Angiomotin interactions without affecting Merlin’s ability to
interact with Pak (Figure 1E; Figure S1H) underscore a previously
underappreciated role of the CC domains in mediating Merlin’s
tumor suppressive function and are consistent with the fact
that patient-derived missense mutations are spread throughout
all domains of the NF2 gene (http://www.sanger.ac.uk/perl/
genetics/CGP/cosmic?action=gene&ln=NF2).
Angiomotin – A Potential Player in NF2 and Other
Merlin-Related Cancers
In this study, we demonstrate that Angiomotin functions as
a positive regulator of the MAPK signaling pathway (Figure 3)
and is required for schwannoma development from Nf2-defi-
cient Schwann cells (Figure 6). Beside schwannomas, NF2
germline and/or somatic mutations predispose patients to
meningiomas and ependymomas. Homozygous NF2 mutations
have been also detected in carcinomas of various tissue origins.
In particular, a recent systematic analysis has indicated thatNF2
mutations define a subtype of non-VHL mutated clear cell renal
carcinomas (ccRCCs) and targeted deletion of Nf2 in mouse
renal epithelia leads to invasive carcinoma by 6–10 months of
age (Dalgliesh et al., 2010; Morris and McClatchey, 2009). In
addition, Nf2-driven liver cancer models have been recently
reported (Benhamouche et al., 2010; Zhang et al., 2010).
Considering our finding that the Angiomotin-Merlin interaction
mediates Merlin’s regulation of Rac1-MAPK signaling in epithe-
lial cells (Figure 3), it would be of interest to examine the role of
Angiomotin in these two cancer models and the status of Angio-
motin in human kidney and liver cancers.
EXPERIMENTAL PROCEDURES
Antiangiomotin and Rich1 Antibodies
Purified rabbit polyclonal Angiomotin and Rich1 antibodies were raised
against peptide sequences CKTPIQILGQEPDAEMVEYLI and GRAEKTEVLSE
DLLQIERR (Thermo Scientific Open Biosystems). Specificity of antibodies was
verifiedwith Angiomotin or Rich1 knockdown cells by IP, IB, and IF (Figures 1F,
3A, and 3B; Figures S1I, S2B, and S2C).
Immunofluorescence
HEK293 or MDCK cells grown on coverslips were washed 33 with cold PBS
and fixed by cold methanol for 5 minutes or by 4% paraformaldehyde for 30
minutes. Coverslips were blocked in 5% goat serum/PBS and 0.3% Triton
X-100. Teased nerve fibers were permeabilized in acetone for 10 minutes,
washed in PBS, blocked for 60 minutes in 5% fish skin gelatin/PBS and
0.5% Triton X-100. For costaining with ZO1 (1:200), E-Cad (1:500), and Flag538 Cancer Cell 19, 527–540, April 12, 2011 ª2011 Elsevier Inc.(1:500) mouse antibodies, endogenous Merlin was detected with rabbit anti-
Merlin (#9168 at 1:50). For costaining with Amot (1:200), mouse anti-Merlin
(b-12 at 1:50) was used. This was followed by incubation with Fluor 488 and
568 conjugated anti-mouse or rabbit secondary antibodies at 1:400 (Invitro-
gen). DAPI (Sigma) was used for nuclear counterstaining. Images were taken
under Zeiss Axioskop 2 fluorescence microscope or Leica TCS SP2 scanning
confocal microscope. Z-stacking images were deconvoluted using Leica
confocal software.
Isolation of Mouse Sciatic Nerve
Three to four month-old mice were euthanized by CO2 and sciatic nerves were
surgically removed, fixed in 4% paraformaldehyde for 10 minutes, and rinsed
in PBS. Nerveswere cut into 1–2 cmpieces, teased into small bundles or single
fibers, and spread onto glass slides. Slides were allowed to dry overnight at
room temperature and stored at 20C.
In Vivo Tumor Models and Imaging
All animal experiments were approved by the Wistar Institutional Animal Care
and Use Committee and performed in accordance with relevant institutional
and national guidelines.
Nf2/ SC4 control or Amot-KD Schwann cells were transduced by lentivi-
ruses carrying pLuc-mCherry and sorted by FACS. Cells (2 3 105 or 5 3 104)
were transplanted into the sciatic nerve sheath of NOD/SCID mice (6–8 weeks
of age) by intraneural injection or injected subcutaneously. Tumor progression
was monitored weekly by bioluminescence imaging (BLI) according
to the manufacturer’s instructions on an IVIS-200 system (Xenogen,
San Francisco, CA).
Statistical Analysis
All data were represented by the mean and standard deviation (SD) was used
to indicate data variability. All statistical analysis was performed with two-
tailed unpaired Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
ccr.2011.02.017.
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